Wavelet Medical Partners with Aegis Ventures to Advance AI Fetal Brain Monitoring
Wavelet Medical has partnered with Aegis Ventures to commercialize an AI-powered fetal brain monitoring platform, announced in a press release. The collaboration includes $7 million in seed funding to bring Wavelet’s non-invasive fetal electroencephalography (EEG) technology from laboratory research to global clinical use.
Developed at Yale, the system uses EEG signals captured through the mother's abdomen and reconstructed with proprietary AI algorithms to detect fetal brain distress in real time. This approach differs from traditional fetal heart rate monitoring by directly measuring neurological activity, aiming to prevent brain injury at birth and reduce unnecessary caesarean sections.
Wavelet’s technology is currently being tested at three clinical sites, including those affiliated with USC and LA General. The company plans to expand trials as it moves toward commercialization. Aegis Ventures, which co-founds healthtech startups with academic and healthcare partners, will support product development, clinical adoption, and global rollout.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly, AI Funding Brief or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
More from: Funding
Subscribe to AI Funding Brief
Whitepaper
Governing the Future: A Strategic Framework for AI Adoption in Financial Institutions
This whitepaper explores the transformative impact of artificial intelligence on the financial industry, focusing on the governance challenges and regulatory demands faced by banks. It provides a strategic framework for AI adoption, emphasizing the importance of a unified AI approach to streamline compliance and reduce operational costs. The document offers actionable insights and expert recommendations for banks with fewer than 2,000 employees to become leaders in compliant, customer-centric AI.
Read more